The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00678522
Recruitment Status : Completed
First Posted : May 15, 2008
Last Update Posted : May 15, 2008
Medical Research
Information provided by:
Regional Hospital Holstebro

May 13, 2008
May 15, 2008
May 15, 2008
September 2007
May 2008   (Final data collection date for primary outcome measure)
GFR, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, albumin excretion rate and free water clearance. [ Time Frame: 6 months ]
Same as current
No Changes Posted
AVP, Ang-II, Aldo, ANP, BNP, PRC, BP, HR. [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes
The Acute Effect of Atorvastatin on Renal Sodium Excretion, Glomerular Filtration Rate, Tubular Function and Vasoactive Hormones in Patients With Non-Insulin Dependent Type II Diabetes.
We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium excretion, glomerular filtration rate, tubular function and vasoactive hormones in patients with type II diabetes, not in treatment with insulin.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Healthy Subjects
Drug: Atorvastatin
80 mg atorvastatin daily on two following days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
May 2008
May 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age: 40-70 yrs
  2. estimated GFR between 30 and 90 ml/min
  3. BMI<35
  4. Fertile women had to use oral contraceptives or IUD
  5. HbA1c< 10%
  6. Urine-albumin<1,5 g/l

Exclusion Criteria:

  1. Treatment with insulin
  2. Cerobrovascular insult or other disease of the brain
  3. Insufficiency of the heart or lungs
  4. Liverdisease with ALAT > 200 U/L
  5. hemoglobin < 7,0 mmol/l
  6. Cancer
  7. Alcohol abuse
  8. Medical treatment with psycopharmaca or/and analgetics
  9. Pregnancy and breast feeding, 10 blood donation one month before the study.
Sexes Eligible for Study: All
40 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Lone Paulsen, Medical Research
Regional Hospital Holstebro
Medical Research
Principal Investigator: Erling B. Pedersen, Professor Dept. of medical reaserch, Holstebro Hospital, Denmark
Regional Hospital Holstebro
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP